Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | VCP | P55072 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 9/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5824218 | 0.86 | HRH3 (0.43) | HRH3VCPTLR9TLR7KDR | |
| SCHEMBL5818162 | 0.86 | TLR9 (0.45) | HRH3TLR9TLR7CARM1KDR | |
| SCHEMBL5950589 | 0.85 | TLR9 (0.54) | TLR9TLR7CARM1TLR8 | |
| SCHEMBL5820341 | 0.84 | NAMPT (0.44) | EGFRVCPTLR9TLR7TLR8 | |
| SCHEMBL5820172 | 0.82 | TLR9 (0.41) | HRH3TLR9TLR7CARM1 | |
| SCHEMBL5822020 | 0.79 | CCNT1 (0.43) | HRH3TLR9TLR7CARM1 | |
| SCHEMBL5817299 | 0.74 | TLR9 (0.64) | TLR9TLR7CARM1TLR8 | |
| SCHEMBL5821888 | 0.73 | DRD2 (0.56) | TLR9TLR7CARM1 | |
| SCHEMBL5824277 | 0.72 | TLR9 (0.66) | TLR9TLR7CARM1TLR8 | |
| SCHEMBL4563607 | 0.71 | HRH3 (0.44) | HRH3CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006113458-A1 | HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | PRMT1, PRMT3, PRMT8 | HRH3 1590/4885EGFR 3138/4885VCP 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.